Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | CTSV | O60911 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3885646 | 0.87 | ALDH1A1 (1.00) | ALDH1A1TDP1CYP3A4ALOX15TP53 | |
| SCHEMBL10691523 | 0.83 | ALDH1A1 (0.58) | ALDH1A1TP53HTTMAPTKDM4E | |
| SCHEMBL7690599 | 0.83 | ALDH1A1 (0.58) | ALDH1A1TDP1CYP3A4ALOX15TP53 | |
| SCHEMBL29994274 | 0.82 | ALDH1A1 (0.64) | ALDH1A1TDP1CYP3A4ALOX15TP53 | |
| SCHEMBL11443974 | 0.82 | ALDH1A1 (0.64) | ALDH1A1TDP1CYP3A4ALOX15TP53 | |
| Trimethylammonium SCHEMBL9860952 | 0.80 | ALDH1A1 (0.62) | ALDH1A1TDP1CYP3A4ALOX15TP53 | |
| SCHEMBL6228852 | 0.80 | ALDH1A1 (0.55) | ALDH1A1TDP1CYP3A4ALOX15TP53 | |
| SCHEMBL11819145 | 0.78 | ALDH1A1 (0.64) | ALDH1A1TDP1CYP3A4ALOX15TP53 | |
| SCHEMBL260006 | 0.78 | ALDH1A1 (0.70) | ALDH1A1TDP1CYP3A4ALOX15TP53 | |
| SCHEMBL10363029 | 0.78 | ALDH1A1 (0.52) | ALDH1A1TDP1CYP3A4ALOX15TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223299-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMACEUTICALS, INC. | 2025-07-10 | — | — | US | disclosed |
| US-12297207-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | REGENERON PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| CN-115645543-A | Maytansinoid derivatives, conjugates thereof, and methods of use | 里珍纳龙药品有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20220259225-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | REGENERON PHARMACEUTICALS, INC. | 2022-08-18 | — | — | US | disclosed |
| US-10941115-B2 | Kinase inhibitors | OXULAR ACQUISITIONS LIMITED (GB) | 2021-03-09 | — | — | US | disclosed |
| US-20200385402-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | REGENERON PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-20190330155-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
| EP-3273998-B1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMA (US) | 2019-09-04 | — | — | EP | disclosed |
| US-10392346-B2 | Kinase inhibitors | TOPIVERT PHARMA LIMITED (GB) | 2019-08-27 | — | — | US | disclosed |
| US-10125100-B2 | Kinase inhibitors | RESPIVERT LIMITED | 2018-11-13 | — | — | US | disclosed |
| US-4746658-A | 2-phenyl-imidazo-pyrazines, -pyridazines and -triazines | DR. KARL THOMAE GMBH (DE) | 1988-05-24 | — | — | US | disclosed |
| US-4722929-A | Novel 2-phenyl-imidazoles and pharmaceutical compositions containing same | DR. KARL THOMAE GMBH (DE) | 1988-02-02 | — | — | US | disclosed |
| US-4696931-A | CARDIOVASCULAR DISORDERS, CARDIOTONIC AGENTS | DR. KARL THOMAE GMBH (DE) | 1987-09-29 | — | — | US | disclosed |
| US-4656171-A | 2-phenyl-imidazo-pyrazines, useful as cardiotonics | DR. KARL THOMAE GMBH (DE) | 1987-04-07 | — | — | US | disclosed |
| US-4582837-A | Imidazo[4,5-b] and [4,5-c]pyridine derivatives having cardiotonic activity | DR. KARL THOMAE GMBH (DE) | 1986-04-15 | — | — | US | disclosed |
| EP-0149200-A1 | Novel 2-pnenyl-imidazoles, their preparation and drugs containing them | Dr. Karl Thomae GmbH (DE) | 1985-07-24 | — | — | EP | disclosed |
| EP-0148438-A2 | Imidazole derivatives, their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1985-07-17 | — | — | EP | disclosed |
| EP-0098448-A2 | Imidazole derivatives, their preparation and medicines containing these compounds | Dr. Karl Thomae GmbH (DE) | 1984-01-18 | — | — | EP | disclosed |
| EP-0023569-B1 | DERIVATIVES OF CARBOXYLIC ACIDS, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1983-06-22 | — | — | EP | disclosed |
| EP-0023569-A1 | Derivatives of carboxylic acids, their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1981-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250223299-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | SLC10A1, HNMT, OGFR | ALDH1A1 317/4885TDP1 1130/4885CYP3A4 1529/4885 |
| US-20200385402-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | SLC10A1, HNMT, OGFR | ALDH1A1 317/4885TDP1 1130/4885CYP3A4 1529/4885 |
| US-12297207-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | SLC10A1, HNMT, OGFR | ALDH1A1 317/4885TDP1 1130/4885CYP3A4 1529/4885 |
| US-10125100-B2 | Kinase inhibitors | SYK, LYN, SRC | ALDH1A1 4454/4885TDP1 1981/4885CYP3A4 2692/4885 |
| US-20190330155-A1 | KINASE INHIBITORS | SYK, LYN, BTK | ALDH1A1 4377/4885TDP1 1390/4885CYP3A4 2185/4885 |
| US-10941115-B2 | Kinase inhibitors | SYK, LYN, BTK | ALDH1A1 4377/4885TDP1 1390/4885CYP3A4 2185/4885 |
| US-10392346-B2 | Kinase inhibitors | LYN, SYK, BTK | ALDH1A1 4056/4885TDP1 1294/4885CYP3A4 1611/4885 |
| US-20220259225-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | SLC10A1, HNMT, OGFR | ALDH1A1 317/4885TDP1 1130/4885CYP3A4 1529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.